Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
United States Commercial Medical Device

LPath Merger Will Take Apollo Endosurgery Public

  • News

Executive Summary

Obesity device firm Apollo Endosurgery and drug firm LPath Inc. have announced plans to merge in an agreement that is intended to transition the privately held Apollo into a NASDAQ-listed company.

You may also be interested in...



Business Briefs: Knee, Obesity Approvals, And A Deal Roundup

Key approvals for Stryker and Apollo Endosurgery, and deals by Boston Scientific, Illumina, Abbott and Lombard Medical.

Strike two for Lpath, employees out

Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217

The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.

Table

View full table

Topics

Related Companies

Tags:
United States Commercial Medical Device
Latest Headlines

Second EU MDR Notified Body Designated In France

Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217

CDS Final Guidance Draws More Criticism, This Time From Congress

Alarming Rise Of Diabetes in Several US States, Study Shows

See All
UsernamePublicRestriction

Register

MT103824

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By